Vaxine is pleased to see its latest Covid-19 vaccine Phase 2 trial results complete peer review and be published in the journal “Clinical Microbiology and Infection”, the official journal of the European Society of Clinical Microbiology and Infectious Diseases. This paper investigates the immunogenicity ad efficacy of Vaxine’s vaccine composed of a recombinant prefusion-stabilized SARS-CoV-2...
The Therapeutic Goods Administration (TGA), part of the Department of Health, has granted provisional determination to Vaxine Pty Ltd in relation to its COVID-19 vaccine: Recombinant CoV-2-S-ΔTM protein with Advax-CpG55.2 (active ingredient name and tradename to be confirmed). This recombinant (genetically engineered) protein vaccine will be considered for active immunisation to prevent COVID-19 caused by SARS-CoV-2. If...
Amid the COVID-19 pandemic and the development of new vaccines, we hear the term “vaccine efficacy” more than ever. But, this raises some questions: what do these efficacy numbers exactly mean? How do the researchers calculate these numbers? And, how should these numbers be interpreted? Vaccine candidates undergo clinical trials to determine vaccine efficacy, and...
This latest paper highlights a Herpes simplex virus vaccine being developed in collaboration with our Swedish partners. The Advax-CpG adjuvant in this herpes simplex vaccine is the same approach as we are using in our current COVID-19 vaccine. Link to the paper: https://www.sciencedirect.com/science/article/pii/S0264410X21010987
On August 07, 2021, the first volunteer enrolled in the Phase 3 clinical study of Cinnagen’s COVID-19 vaccine candidate in Iran. The study is a randomized, double-blind, placebo-controlled trial and will evaluate the efficacy and safety of the vaccine in 16,876 adult participants. Subjects receive two doses, 21 days apart, of either COVID-19 vaccine or saline placebo...